enGene Holdings Inc. (ENGN), which reported promising initial efficacy and safety data from the pivotal cohort of its LEGEND trial of Detalimogene voraplasmid last year, is expected to provide an update this quarter.
Detalimogene is a novel, investigational, non-viral gene-based immunotherapy for patients with high-risk non-muscle-invasive bladder cancer, including Bacillus Calmette-Guérin (BCG)-unresponsive disease. It is designed to be instilled in the bladder and elicit a powerful yet localized anti-tumour immune response.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.